Zobrazeno 1 - 10
of 266
pro vyhledávání: '"Robert J Binder"'
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e50365 (2012)
The cell surface receptor CD91/LRP-1 binds to immunogenic heat shock proteins (HSP) and α(2)M ligands to elicit T cell immune responses. In order to generate specific immune responses, the peptides chaperoned by HSPs or α(2)M are cross-presented on
Externí odkaz:
https://doaj.org/article/e5d825a645d249f3ada085552f0fd415
Autor:
David O. Osei-Hwedieh, Abigail L. Sedlacek, Luis Mena Hernandez, Archibald Agyekum Yamoah, Swati G. Iyer, Kurt R. Weiss, Robert J. Binder
Publikováno v:
JCI Insight, Vol 8, Iss 13 (2023)
T cells recognize tumor-derived mutated peptides presented on MHC by tumors. The recognition of these neo-epitopes leads to rejection of tumors, an event that is critical for successful cancer immunosurveillance. Determination of tumor-rejecting neo-
Externí odkaz:
https://doaj.org/article/d8f0223374d04824b7fc12598b9767b9
Autor:
Devanshi A. Nayak, Robert J. Binder
Publikováno v:
Trends Immunol
Tumor immunosurveillance requires tumor cell-derived molecules to initiate responses through corresponding receptors on antigen presenting cells (APCs) and a specific effector response designed to eliminate the emerging tumor cells. This is supported
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5ae3cfd6a0bd5b60796482b67fcb115
https://europepmc.org/articles/PMC9058224/
https://europepmc.org/articles/PMC9058224/
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 11, Iss 1 (2022)
article-version (VoR) Version of Record
OncoImmunology, Vol 11, Iss 1 (2022)
Antibodies and T cells specific for tumor-associated antigens (TAA) are found in individuals without cancer but with a history of infections and are associated with lowered cancer risk. We hypothesized that those immune responses were generated to tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7585932217780f21d90a0ff80260ca4a
http://europepmc.org/articles/PMC8786340
http://europepmc.org/articles/PMC8786340
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
The release of Heat Shock Proteins (HSPs) from aberrant cells can initiate immune responses following engagement of the HSPs with antigen presenting cells (APCs). This is an important mechanism for cancer immunosurveillance and can also be modeled by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::681aff4b23fa6a8646591204a47b21b9
http://europepmc.org/articles/PMC8352880
http://europepmc.org/articles/PMC8352880
Autor:
Abigail L Sedlacek, David Osei-Hwedieh, Archibald Agyekum-Yamoah, Luis Mena, Swati Iyer, Kurt Weiss, Robert J Binder
Publikováno v:
The Journal of Immunology. 208:179.12-179.12
T cells recognize tumor neoantigens (TNag) in the context of MHC and eliminate cells which express these antigens, leaving those lacking immunodominant epitopes. Central to investigating tumor immunoediting is the ability to define immunogenic TNag.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95ce8529fce6cdc4464b3a2edf02e3a8
https://doi.org/10.4049/jimmunol.208.supp.179.12
https://doi.org/10.4049/jimmunol.208.supp.179.12
Autor:
James F Harkness, Robert J Binder
Publikováno v:
The Journal of Immunology. 208:61.07-61.07
Cancer immunosurveillance is dependent on the heat shock protein (HSP) receptor, CD91, which is expressed on professional antigen-presenting cells (APCs). While CD91-facilitated cross-presentation of HSP-chaperoned peptides has been well studied, CD9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0e83bb0dd36a7d2899484e3bbe9a912
https://doi.org/10.4049/jimmunol.208.supp.61.07
https://doi.org/10.4049/jimmunol.208.supp.61.07
Autor:
Devanshi A Nayak, Robert J Binder
Publikováno v:
The Journal of Immunology. 208:61.15-61.15
The immune system detects and eliminates nascent, emerging tumor cells. This is mediated primarily by T cells and NK cells. However, the mechanisms that allow efficient T cell priming during cancer immunosurveillance, which is characterized by limite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4834c6dfc426351ed33d266a0d73dc36
https://doi.org/10.4049/jimmunol.208.supp.61.15
https://doi.org/10.4049/jimmunol.208.supp.61.15
Autor:
Tatiana Shcheglova, Yu Jerry Zhou, Ion I. Mandoiu, Robert J. Binder, Theodore P Younker, Lisa Borghesi, Abigail L. Sedlacek
Publikováno v:
JCI Insight. 4
The immune system detects aberrant, premalignant cells and eliminates them before the development of cancer. Immune cells, including T cells, have been shown to be critical components in eradicating these aberrant cells, and when absent in the host,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c96b8d1c2d9a9555091e7116d0b05599
https://doi.org/10.1172/jci.insight.127239
https://doi.org/10.1172/jci.insight.127239
Autor:
Devanshi A Nayak, Robert J Binder
Publikováno v:
The Journal of Immunology. 206:101.10-101.10
The premise of immunosurveillance is that the immune system, particularly T cells, can detect and eliminate emerging tumor cells. However, the mechanisms that allow efficient T cell priming during nascent tumor immunosurveillance despite limited anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2de7da9191a85f22ec2719931800cbed
https://doi.org/10.4049/jimmunol.206.supp.101.10
https://doi.org/10.4049/jimmunol.206.supp.101.10